2023
Clinical data imminent!
6 February 2024
Beating bacteria just got boosted
11 November 2023
Immuron hails record monthly sales of Travelan
18 September 2023
Q&A with Steven Lydeamore, CEO of Immuron Limited
23 August 2023
Sequire Spotlight Presents Immuron Limited (IMRN): Creating New Products for Infectious Diseases
24 July 2023
Immuron on How their Gastrointestinal and Digestive Health Immune Supplements Work + FY23 Sales
20 July 2023
Immuron Sees Substantial Sales Growth in FY23 Driven by Resurgence in Travel (ASX:IMC)
18 July 2023
Immuron to go ahead with IMM-529 cGMP manufacturing and proceed with FDA pre-IND submission
27 June 2023
Immuron Limited Announces Participation in the LD Micro Invitational XIII
6 June 2023
Innovation begins with collaboration: Steven Lydeamore
5 April 2023
Immuron grows revenue by 153% in H1 FY23 with more growth catalysts lined up
1 March 2023
Immuron Limited CEO Steven Lydeamore interview with Stuart Roberts Management Interview Series – Stocks Down Under
28 February 2023
US recruitment milestone for trial of Immuron's Travelan
19 January 2023
Immuron working towards US FDA approval of Traveler’s Diarrhea product Travelan
18 January 2023